tazarotene topical / Generic mfg. |
ChiCTR1900026812: Clinical Study of Post-Marketing Efficacy and Safety of Tazarotene Betamethasone Cream in the Treatment of Chronic Psoriasis Vulgaris |
|
|
| Completed | 4 | 2299 | | Tazarotene and Betamethasone Dipropionate Cream (once daily) | Peking Union Medical College Hospital; Chongqing Huapont Pharm.Co., LTD, Chongqing Huapont Pharm.Co.,LTD | Chronic Psoriasis Vulgaris | | | | |
ChiCTR1900027060: A Multicenter, Randomized, Open-Label Clinical Trial of Tazarotene and Betamethasone Dipropionate Cream Alone or Sequentially With Tazarotene Gel In the Treatment of Chronic Plaque Psoriasis |
|
|
| Completed | 4 | 232 | | Tazarotene and Betamethasone Dipropionate Cream (once daily) ;Tazarotene and Betamethasone Dipropionate Cream (on weekends); Tazarotene Gel (on workdays) | Chinese Academy of Medical Sciences & Hospital for Skin Diseases; Chongqing Huapont Pharm.Co., Ltd., Chongqing Huapont Pharm.Co.,LTD | Chronic Plaque Psoriasis | | | | |
NCT05555797: Excimer Laser With Topical Agents in Psoriasis Vulgaris |
|
|
| Not yet recruiting | 4 | 30 | NA | 308nm Excimer laser, Tazarotene Topical Gel, Betamethasone Valerate | Assiut University | Psoriasis | 09/23 | 09/23 | | |
ChiCTR1900024450: A phase III, multicenter, randomized, blind, controlled trial for efficacy and safety of tazarotene and betamethasone dipropionate cream in the treatment of subjects with psoriasis vulgaris |
|
|
| Completed | 3 | 600 | | 0.05% betamethasone dipropionate cream (Applied twice daily in the morning and evening) ;Placebo(once in the morning) +0.05% tazarotene gel (once in the evening) ;Placebo (once in the morning) + Tazarotene and Betamethasone Dipropionate Cream (once in the evening) | Chinese Academy of Medical Sciences & Hospital for Skin Diseases; Chongqing Huapont Pharm.Co., LTD, Chongqing Huapont Pharm.Co.,LTD | Psoriasis vulgaris | | | | |
2013-003336-72: Clinical study for patients with cutaneous basal cell tumor evaluating the role of topical DAC-0600 plus Tazarotene Studio clinico per pazienti con tumore basocellulare della pelle per valutare il ruolo del trattamento locale con DAC-0060 in associazione a Tazarotene |
|
|
| Ongoing | 2 | 80 | Europe | ZORAC, DAC-0060, Gel, ZORAC | ISTITUTO EUROPEO DI ONCOLGIA, DAC srl | BASAL CELL CARCINOMA carcinoma basocellulare cutaneo, SKIN CANCER TUMORE CUTANEO, Diseases [C] - Cancer [C04] | | | | |
NCT05314127: Efficacy of Tazarotene in Treatment of Verruca Plana |
|
|
| Recruiting | 2 | 80 | RoW | Tazarotene 0.1% Gel,Top, Imiquimod, Fluorouracil Cream, Petrolatum | Zagazig University | Warts Flat | 10/22 | 12/22 | | |
| Recruiting | 2 | 36 | Europe, US | Tazarotene (GRI-0621), Placebo | GRI Bio Operations, Inc. | Idiopathic Pulmonary Fibrosis | 01/25 | 01/25 | | |
NCT06015152: Comparison Of Efficacy Of Tazarotene 0.045% Vs Halobetasol Propionate 0.01% Lotion For Treatment of Scalp Psoriasis |
|
|
| Completed | N/A | 90 | RoW | Tazarotene 0.045% Topical Application Lotion [ARAZLO] | Jinnah Postgraduate Medical Centre | Scalp Psoriasis | 12/22 | 02/23 | | |